Botulinum toxin in the treatment of facial dystonia: Evaluation of its efficacy and patients' satisfaction along the treatment;Toxina botulínica no tratamento de distonias faciais: Avaliação da eficácia e da satisfação dos pacientes ao longo do tratamento

Arquivos Brasileiros de Oftalmologia

Volumn 68, Issue 4, 2005, Pages 471-474

  Costa, Patrícia Gravito ^a,b   Aoki, Líbia ^a   Saraiva, Fábio Perenes ^a   Matayoshi, Suzana ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b USP ^*  (Brazil)

Author keywords

Blepharospasm therapy; Botulinum toxin type A administration dosage; Botulinum toxin type A therapeutic use; Hemifacial spasm; Patient acceptance of health care; Patient satisfaction; Recurrence

Indexed keywords

BOTULINUM TOXIN A;

ARTICLE; BLEPHAROSPASM; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DYSTONIA; FACE; HUMAN; MUSCLE SPASM; PATIENT SATISFACTION; RETROSPECTIVE STUDY; SCORING SYSTEM; SIDE EFFECT; TREATMENT OUTCOME;

EID: 29244473839     PISSN: 00042749     EISSN: 16782925     Source Type: Journal    
DOI: 10.1590/s0004-27492005000400010     Document Type: Article

References (13)

1. Gonnering RS. Blepharospasm and hemifacial spasm. In: Dortzbach RK. Ophthalmic plastic surgery: prevention and management of complications. New York: Raven Press; 1994. p.141-55.
2. Matayoshi S, Forno E, Moura EM. Blefaroespasmo essencial. In: Nano-Costa M. Schellini AS, Moura EM. Manual de cirurgia plástica ocular. São Paulo: Roca; 2003. p.127-35.
3. Carvalho RML, Gomi CF, Matayoshi S, Moura EM. Tratamento do blefaroespasmo e distonias faciais correlatas com toxina botulínica - estudo de 16 casos. Arq Bras Oftalmol. 2003;66(1):13-7.
4. Machado FCN, Fregni F, Campos CR, Limongi JCP. Espasmo hemifacial bilateral. Relato de caso. Arq Neuropsiquiatr. 2003;61(1):115-8.
5. Cunha CC, Aguirre PA, Souza Dias CR. Tratamento do espasmo facial unilateral com toxina botulínica tipo A. Arq Bras Oftalmol. 1998;61(1):54-60.
6. Tucha O, Naumann M, Berg D, Alders GL, Lange KW. Quality of life in patients with blefaroespasm. Acta Neurol Scand. 2001;103(1):49-52.
7. Price J, O'Day J. Efficacy and side effects of botulinum toxin treatment for blepharospasm and hemifacial spasm. Aust N Z J Ophthalmol. 1994;22(4):255-60.
8. Jitpimolmard S, Tiamkao S, Laopaibonn M. Long term results of botulinum toxin type A (Dysport) in the treatment of hemifacial spasm: report of 175 cases. J Neurol Neurosurg Psychiatry. 1998;64(6):751-7.
9. Snir M, Weinberger D, Bourla D, Cristal-Shalit O, Dotan G, Axer-Siegel R. Quantitative changes in botulinum toxin a treatment over time in patients with essential blefarospasm and idiophatic hemifacial spasm. Am J Ophthalmol. 2003;136(1):99-105.
10. Dressler D. Clinical features of antibody-induced complete secondary failure of botulinum toxin therapy. Eur Neurol. 2002;48(1):26-9.
11. Defazio G, Abbruzzese G, Girlanda P, Vacca L, Curra A, De Salvia R, et al. Botulinum toxin a treatment for primary hemifacial spasm: a 10-year multicenter study. Arch Neurol. 2002;59(3):418-20.
12. Drummond GT, Hinz BJ. Botulinum toxin for blefarospasm and hemifacial spasm: stability of duration of effect and dosage over time. Can J Ophthalmol. 2001;36(7):398-403.
13. Ainsworth JR, Kraft SP. Long-term changes in duration of relief with botulinum toxin treatment of essential blefarospasm and hemifacial spasm. Ophthalmology. 1995;102(12):2036-40.